Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-16
2010-02-16
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C514S418000, C514S422000, C514S323000, C514S469000, C514S416000, C544S373000, C544S144000, C546S201000, C548S454000, C548S483000, C548S518000, C548S525000, C548S490000, C549S462000
Reexamination Certificate
active
07662824
ABSTRACT:
The invention is directed to acylhydrazones compounds of Formula I:where R1, R2and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
REFERENCES:
patent: 2352194 (2001-04-01), None
patent: 19829229 (1999-01-01), None
patent: 19946289 (2001-03-01), None
patent: 10117823 (2002-10-01), None
patent: 672659 (1999-01-01), None
patent: 694808 (2001-12-01), None
patent: 1193248 (2002-04-01), None
patent: 1229034 (2005-04-01), None
patent: 11007093 (1999-01-01), None
patent: 11015090 (1999-01-01), None
patent: 11302173 (1999-11-01), None
patent: 9901434 (1999-01-01), None
patent: 99/15500 (1999-04-01), None
patent: 9951579 (1999-10-01), None
patent: 200006566 (2000-02-01), None
patent: 200071509 (2000-11-01), None
patent: 200071511 (2000-11-01), None
patent: 2000071493 (2000-11-01), None
patent: 2001023386 (2001-04-01), None
patent: 2002000661 (2002-01-01), None
patent: 2002028823 (2002-04-01), None
patent: 2002040507 (2002-05-01), None
patent: 2002083630 (2002-10-01), None
patent: 2002085888 (2002-10-01), None
patent: 2002096361 (2002-12-01), None
patent: 2002096426 (2002-12-01), None
patent: 2003037328 (2003-05-01), None
patent: 2003097649 (2003-11-01), None
patent: 2004050619 (2004-06-01), None
patent: 2004056178 (2004-07-01), None
patent: 2005005378 (2005-01-01), None
Wikipedia, definition of “Medicine”.
STN search result STN-11377077A-clear art.
Fahmy et al. Egyptian Journal of Chemistry, (2003), 46(2), 313-327.
Bieche, et al.,Int. J. Cancer82 (1999), pp. 908-910.
Camp et al.,Cancer86 (1999), pp. 2259-2265.
DiRenzo et al.,J. Endocrinol. Invest18 (1995), pp. 134-139.
DiRenzo et al.,Oncogene19 (2000), pp. 1547-1555.
DiRenzo et al.,Int. J. Cancer58(1994), pp. 658-662.
Dunn et al., Journal of Medicinal Chemistry, 1986, 29 (11), 2326-2329.
Ebert et al.,Cancer Res. 54 (1994), pp. 5775-5778.
Fischer et al.,Oncogene. 17 (1998), pp. 733-739.
Ferracini et al.,Oncogene10 (1995), pp. 739-749.
Gohji et al.,J. Clin. Oncol. 18 (2000), pp. 2963-2971.
Hansel et al.,Cancer Res. 2004 Sep 15;10(18 Pt 1):6152-8.
He et al., Sichuan Da Xue Xue Bao Yi Xue Ban. Jan. 2003 ;34(1):78-9, 88 (English Abstract Only; please advise Applicant if the Examiner would like Applicant to submit a complete translation).
Helvitica Chemica Acta, 1928,11, 609-656 (please advise Applicant if the Examiner would like Applicant to submit a complete translation).
Herrera et al., Neoplasia. Jan. 2005;7(1):75-84.
Hjertner et al.,Blood94 (1999), pp. 3883-3888.
Humphrey at al.,Am J. Pathol. 147 (1995), pp. 386-396.
Ichimura et al.,Jpn. J. Cancer Res. 87 (1996), pp. 1063-1069.
Jucker et al.,Leuk. Res. 18 (1994), pp. 7-16.
Juillerat et al., Helvitica Chemica Acta, 1976, 59 (3), 855-866.
Kawano et al., Br J Haematol. Nov. 2004;127 3 :305-7.
Klominek et al.,Int. J. Cancer76 (1998), pp. 240-249.
Knudsen et al., Adv Cancer Res. 2004;91:31-67.
Kraynack et al., Tetrahedron Letters, 1987, 28 35 , 4027-30.
Kuniyasu et al.,Biochem. Biophys. Res. Commun. 189 (1992) , pp. 227-232.
Kuniyasu et al.,Int. J. Cancer55 (1993), pp. 72-75.
Lee et al.,Oncogene19 (2000), pp. 4947-4953.
Lens el et al.,Int J Cancer. 2005 Feb 10;113 4:678-82.
Liu et al., Am.J. Pathol. 142 (1993) , pp. 1155-1162.
Liu et al.,Oncogene. 7(1992), pp. 181-185.
Marfat et al., Tetrahedron Letters, 1998,39 (42), 7679-7682.
Masuya et al., British Journal of Cancer. 2004; 90:1552-1562.
Maulik et al.,Cytokine Growth Factor Rev. 2002 Feb;13(1):41-59.
Mederski et al., Bioorganic and Medicinal Chemistry Letters, 1998,8 (1), 17-22.
Meyer et al., Journal of Medicinal Chemistry , 1997, 40(7), 1049-1062.
Michieli et al., Cancer Cell. 2004 Jul.;6(1):61-73.
Millet et al., Bioorganic and Medicinal Chemistry Letters 2002, 12 (24) 3601-3604.
Moon et al.,Mod. Pathol. 13 (2000), pp. 973-977.
Moriyama et al.,FEBS Lett. 372 (1995), pp. 78-82.
Nakopoulou et al.,Histopathology36 (2000), pp. 313-325.
Nateli et al.,J. Cancer68 (1993), pp. 746-750.
Oda et al.,Hum. Pathol. 31 (2000), pp. 185-192.
Olivero et al.,Br J. Cancer74 (1996), pp. 1862-1868.
Olivero et al.,J. Cancer82 (1999), pp. 640-643.
Park et al., Cancer Res. 59 (1999), pp. 307-310.
Park et al., 1987, Proc Natl Acad Sci U S A. 84(18):6379-83.
Park et al., Apmis 108 (2000), pp. 195-200.
Parrick et al., Tetrahedron Letters, 2003, 44 (35), 6745-6747.
Pisters et al.,J. Urol. 154 (1995), pp. 293-298.
Plimmer et al., Journal of Agricultural and Food Chemistry, 1969, 17, 83-85.
Poissonnet, G., Synthetic Communications, 1997, 27 (22), 3839-3846.
Ragan et al., Synthesis, 1998, 11, 1599-1603.
Rygaard et al.,Br J. Cancer67 (1993), pp. 37-46.
Sazuki et al.,Hepatology20 (1994), pp. 1231-1236.
Schiemann et al., Organic Syntheses, 13, 525, 1933.
Schmidt et al.,Cancer Res. 58 (1998), pp. 1719-1722.
Schmidt et al.,Oncogene18(1999), pp. 2343-2350.
Searcey et al., Tetrahedron Letters, 1984, 25 (29), 3099-3100.
Settimo et al., European Journal of Medicinal Chemistry 1983, 18(3), 261-267.
Shiebley et al., Journal of Organic Chemistry, 1956, 21, 171-173.
Siegfried et al.,Ann Thorac. Surg. 66 (1998), pp. 1915-1918.
Somei et al., Chemical and Pharmaceutical Bulletin 1981, 29(11), 3145.
Sowter et al.,Int. J. Cancer83 (1999), pp. 476-480.
Sun et al., Bioorganic and Medicinal Chemistry Letters, 2004, 14(14), 3799-3802.
Takanami et al.,Oncology53 (1996), pp. 392-397.
Thirkettle et al.,Histopathology36 (2000), pp. 522-528.
Tokunou et al.,Am J. Pathol. 158 (2001), pp. 1451-1463.
Tolnay et al.,J. Cancer Res. Clin. Oncol. 124 (1998), pp. 291-296.
Tsukinoki et al., Oncol Rep. 2004 Nov.;12(5):1017-21.
Umeki et al.,Oncology56 (1999), pp. 314-321.
Vinot, Bulletin de la Societe Chimique de France, 1964, 2, 245-247 (please advise Applicant if the Examiner would like Applicant to submit a complete translation).
Wang et al., Organic Letters, 2002, 4(16), 2675-2678.
Zhuang et al.,Nat Genet20 (1998), pp. 66-69.
Zeng et al., Clin Exp Metastasis. 2004;21(5):409-17.
International Search Report re: PCT/US2006/009425 dated Jul. 31, 2006.
Alexander Richard S.
Connors Richard W.
Cummings Maxwell D.
Galemmo Robert A.
Johnson Dana L.
Chu Yong
Janssen Pharmaceutica NV
LandOfFree
Acylhydrazones as kinase modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylhydrazones as kinase modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylhydrazones as kinase modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4184691